Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.13
GENE's Cash to Debt is ranked higher than
62% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. GENE: 1.13 )
GENE' s 10-Year Cash to Debt Range
Min: 1.13   Max: No Debt
Current: 1.13

Equity to Asset 0.27
GENE's Equity to Asset is ranked lower than
51% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. GENE: 0.27 )
GENE' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.88
Current: 0.27

0.27
0.88
F-Score: 2
Z-Score: -18.75
M-Score: 1.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -203.82
GENE's Operating margin (%) is ranked higher than
54% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. GENE: -203.82 )
GENE' s 10-Year Operating margin (%) Range
Min: -313.93   Max: 5.73
Current: -203.82

-313.93
5.73
Net-margin (%) -207.89
GENE's Net-margin (%) is ranked higher than
53% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. GENE: -207.89 )
GENE' s 10-Year Net-margin (%) Range
Min: -496.89   Max: 4.98
Current: -207.89

-496.89
4.98
ROE (%) -396.12
GENE's ROE (%) is ranked lower than
55% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. GENE: -396.12 )
GENE' s 10-Year ROE (%) Range
Min: -271.23   Max: 14.99
Current: -396.12

-271.23
14.99
ROA (%) -196.52
GENE's ROA (%) is ranked lower than
56% of the 302 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.41 vs. GENE: -196.52 )
GENE' s 10-Year ROA (%) Range
Min: -134.56   Max: 10.58
Current: -196.52

-134.56
10.58
ROC (Joel Greenblatt) (%) -3548.96
GENE's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 301 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.48 vs. GENE: -3548.96 )
GENE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2051.16   Max: 71.57
Current: -3548.96

-2051.16
71.57
Revenue Growth (3Y)(%) -41.50
GENE's Revenue Growth (3Y)(%) is ranked higher than
53% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. GENE: -41.50 )
GENE' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 58.7
Current: -41.5

0
58.7
» GENE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

GENE Guru Trades in Q2 2014

Jim Simons 18,000 sh (New)
» More
Q3 2014

GENE Guru Trades in Q3 2014

Jim Simons 108,800 sh (+504.44%)
» More
Q4 2014

GENE Guru Trades in Q4 2014

Jim Simons 294,000 sh (+170.22%)
» More
Q1 2015

GENE Guru Trades in Q1 2015

Jim Simons 650,780 sh (+1006.77%)
» More
» Details

Insider Trades

Latest Guru Trades with GENE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 4.00
GENE's P/S is ranked higher than
65% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.41 vs. GENE: 4.00 )
GENE' s 10-Year P/S Range
Min: 0.88   Max: 64
Current: 4

0.88
64
EV-to-EBIT -3.71
GENE's EV-to-EBIT is ranked higher than
65% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. GENE: -3.71 )
GENE' s 10-Year EV-to-EBIT Range
Min: -36.1   Max: 121
Current: -3.71

-36.1
121
Current Ratio 1.88
GENE's Current Ratio is ranked higher than
61% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. GENE: 1.88 )
GENE' s 10-Year Current Ratio Range
Min: 1.08   Max: 5.22
Current: 1.88

1.08
5.22
Quick Ratio 1.79
GENE's Quick Ratio is ranked higher than
64% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. GENE: 1.79 )
GENE' s 10-Year Quick Ratio Range
Min: 0.99   Max: 5.22
Current: 1.79

0.99
5.22
Days Inventory 33.05
GENE's Days Inventory is ranked higher than
88% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 137.36 vs. GENE: 33.05 )
GENE' s 10-Year Days Inventory Range
Min: 20.08   Max: 42.4
Current: 33.05

20.08
42.4
Days Sales Outstanding 68.89
GENE's Days Sales Outstanding is ranked higher than
75% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 78.80 vs. GENE: 68.89 )
GENE' s 10-Year Days Sales Outstanding Range
Min: 8.08   Max: 58.92
Current: 68.89

8.08
58.92

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.90
GENE's Price/Median PS Value is ranked higher than
80% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. GENE: 0.90 )
GENE' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 15.25
Current: 0.9

0.38
15.25
Earnings Yield (Greenblatt) -27.00
GENE's Earnings Yield (Greenblatt) is ranked lower than
53% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. GENE: -27.00 )
GENE' s 10-Year Earnings Yield (Greenblatt) Range
Min: -27   Max: 1804.9
Current: -27

-27
1804.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:GTG.Australia, GNTLF.USA, DU8.Germany,
Genetic Technologies Ltd is incorporated in Australia on January 05, 1987. The Company is a biotechnology company focused on expanding genetic testing business in the Asia-Pacific region and, with the addition of the BREVAGenTM breast cancer risk assessment test, in the U.S.A. and later in Europe. In addition, it is now pursuing commercial opportunities in other areas of activity: out-licensing non-coding patents; and supporting a late-stage research and development project in which it is already involved. The patents in the portfolio includes ntron Sequence Analysis; Genomic Mapping; Perlegen; BREVAGenTM; Laboratory Techniques; Ancestral Haplotypes; Athletic Performance;Nematode Project; and RareCellect Project.
» More Articles for GENE

Headlines

Articles On GuruFocus.com
Genetic Technologies Appoints Eutillio Buccilli as Chief Executive Officer Feb 26 2015 
Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment Dec 17 2014 
Genetic Technologies Launches BREVAGenplus(R) Breast Cancer Risk Assessment Test Oct 15 2014 
Genetic Technologies Announces Quarterly BREVAGen(TM) Results Oct 15 2014 

More From Other Websites
ROCKVILLE GYNECOLOGY NOW OFFERING BREVAGenplus(R), A STATE-OF-THE-ART TEST FOR ASSESSING BREAST... May 11 2015
Shires Earnings Just Made The Best Drug Reformulation Story Even Better May 01 2015
Genetic Technologies Drives Ahead in the Fight Against Cancer Apr 20 2015
Genetic Technologies (GENE) Rises Today as More Centers Adopt Breast Cancer Test Apr 20 2015
Genetic Technologies Announces: Additional Breast Health Centres to Begin Offering BREVAGenplus(R) Apr 20 2015
These 5 Stocks Have More Than Doubled In 2015 Apr 06 2015
These are the most profitable Nasdaq biotech companies Mar 02 2015
Genetic Technologies Appoints Eutillio Buccilli as Chief Executive Officer Feb 26 2015
The Trade Traders are Waiting for in Genetic Technologies ($GENE) Feb 19 2015
Genetic Technologies Announces up to 6 New Breast Centres to Begin Offering BREVAGenplus(R) Jan 29 2015
Genetic Technologies Secures A$24 Million Standby Equity Placement Facility Jan 21 2015
Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment Dec 17 2014
GENETIC TECHNOLOGIES LTD Financials Nov 04 2014
Genetic Technologies Announces Quarterly BREVAGen(TM) Results Oct 06 2014
Genetic Technologies Launches BREVAGenplus(R) Breast Cancer Risk Assessment Test Oct 01 2014
Genetic Technologies Announces Appointment of Independent Non-Executive Directors Sep 24 2014
Genetic Technologies Announces Divestment of Australian Based Heritage Business Sep 22 2014
Transformational Restructuring Plans to Support Molecular Diagnostics Focus and Finalisation of... Sep 15 2014
Genetic Technologies Announces Further Patent Success in USA Aug 26 2014
Why Genetic Technologies (GENE) Stock Is Spiking Today Jul 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK